Name
C1q, Mouse, mAb 7H8
Catalog nr
HM1044 (lot number and expiry date are indicated on the label)
Short description
The monoclonal antibody 7H8 recognizes mouse CIq. Clq, a member of the 'defense collagen' family, is the first subcomponent of the Cl complex of the classical pathway of complement activation. Several functions have been assigned to the pattern recognition molecule Clq, which include antibody-dependent and independent immune functions like triggering of rapid enhanced phagocytosis resulting in...
Size
100 µg
Application
F , IA , IP
Technical datasheet
Description
The monoclonal antibody 7H8 recognizes mouse CIq. Clq, a member of the 'defense collagen' family, is the first subcomponent of the Cl complex of the classical pathway of complement activation. Several functions have been assigned to the pattern recognition molecule Clq, which include antibody-dependent and independent immune functions like triggering of rapid enhanced phagocytosis resulting in efficient containment of pathogens or clearance of cellular debris, apoptotic cells and immune complexes , and is considered to be mediated by Clq receptors present on the effector cell surface. There remains some uncertainty about the identities of the receptors that mediate Clq functions. Some of the previously described Clq receptor molecules, such as gClqR and cClqR, now appear to have less of a role in Clq functions than in functions unrelated to Clq. Experiments with gene targeted homozygous Clq-deficient mice have suggested a role for Clq in modulation of the humoral immune response, and also in protection against development of autoimmunity. The first component of complement Cl is a complex of three glycoproteins - Clq, Clr, and Cls. Cls and Clr interact to form a Cazf-dependent tetrameric proenzyme complex, C lr,-C 1 s2, which makes contacts with the Clq collagen domain. Binding of Clq to immune complexes (IgG or IgM) via the gClq domain, is considered to induce a conformational change in the collagen region of Clq, which leads to the autoactivation of Clr which, in turn, activates Cls. The activated Cl complex then cleaves components C4 and C2 in the classical complement cascade.
Cross Reactivity
 Cross reactant  Reactivity
 Mouse     Yes
Formulation
1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
Species
Rat IgG1
Application

 

F1,4

FC

FS3

IA5

IF2,3

IP

P

W

Yes

 

 

 

 

No

 

 

 

 

 

 

 

 

N.D.

 

 

 

 

 

N.D.= Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Fluorescence; IP = Immuno Precipitation; P = Paraffin sections; W = Western blot
Application notes
F:4% PFA fixed and sucrose infiltrated frozen tissue. 18h 4C, 0.133 ug/ml 7H8 IA: To detect bound C11, 1/100 diluted
Use
For immunohistochemistry, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.
Positive control
Macrophages, follicular dendritic cells
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
References
  1. Zachrau, B et al; Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice. Int Immunol 2004, 16: 1685
  2. Kang, Y et al; A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q. Cell 2006, 125: 47
  3. Abbitt, K et al; Antibody ligation of murine Ly-6G induces neutropenia, blood flow cessation, and death via complement-dependent and independent mechanisms. J Leukoc Biol 2009, 85: 55
  4. Ankeny, D et al; B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 2009, 119: 2990
  5. Suresh_m et al; Role of the property of C-Reactive Protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol 2006, 176: 4369
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Also available
References
  1. Zachrau, B et al; Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice. Int Immunol 2004, 16: 1685
  2. Kang, Y et al; A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q. Cell 2006, 125: 47
  3. Abbitt, K et al; Antibody ligation of murine Ly-6G induces neutropenia, blood flow cessation, and death via complement-dependent and independent mechanisms. J Leukoc Biol 2009, 85: 55
  4. Ankeny, D et al; B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 2009, 119: 2990
  5. Suresh_m et al; Role of the property of C-Reactive Protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol 2006, 176: 4369
Related products Cat #
C3, Mouse, mAb 11H9 HM1045
C4, Mouse, mAb 16D2 HM1046
C1q, Mouse, mAb JL-1 HM1096
C3, Mouse, pAb HP8012